Conservative Management for PAS Pilot

Not Applicable

Recruiting

• Conditions: Placenta Accreta
• Interventions: Procedure: Conservative management for placenta accreta spectrum (PAS); Procedure: Cesarean hysterectomy for placenta accreta spectrum (PAS)

• Registration Number: NCT05139498
• Lead Sponsor: University of Utah

Brief Summary

Conservative in situ management is a promising alternative treatment to hysterectomy for patients with placenta accreta spectrum and may be safer and preferable for some patients. This study will assess feasibility of a future randomized clinical trial comparing these treatments and provide novel data to inform shared decision-making and cost-effective care for patients with this deadly pregnancy disorder.

Detailed Description

Placenta accreta spectrum (PAS) is an extremely morbid and increasingly common pregnancy condition that often results in massive obstetric hemorrhage. The standard treatment in the United States is hysterectomy, but this treatment is complex, morbid, and costly. A promising alternative for PAS treatment is conservative in situ management (CM), a strategy in which the placenta is left in the uterus. Unfortunately, there are insufficient data available to compare outcomes of these two treatments because past studies are limited by non-randomized study designs, minimal inclusion of patient values in making treatment decisions, and nominal consideration of economic barriers to care. A large clinical trial comparing PAS treatments is needed. But there are key logistic barriers to an adequately powered trial, including questions of whether patients will enroll and adhere to randomization allocation. This pilot trial will evaluate the feasibility of randomizing patients to CM versus hysterectomy for PAS.

While pilot studies cannot make final assessments of safety and efficacy between interventions, safety and efficacy will be monitored, including those related to hemorrhage, transfusion, infection and re-operation.

Study Timeline

• Study First Submitted: 2021-10-13
• Study First Submitted QC: 2021-11-17
• Study First Posted: 2021-12-01
• Study Start: 2022-05-26
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-14
• Last Update Posted: 2025-04-16
• Primary Completion: 2026-03
• Study Completion: 2026-06-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 32

Inclusion Criteria

• Age 18 and older
• History of cesarean delivery AND placenta previa OR anterior low-lying placenta AND suspected of having PAS on prenatal imaging (ultrasound/MRI)
• Patients who would typically be recommended for hysterectomy
• Planned delivery between 34w0d and 36w0d gestation.

Exclusion Criteria

• Plan to delivery before neonatal viability (<24 weeks gestation)
• Hospitalized for antenatal hemorrhage
• Have a low antenatal suspicion for PAS based on imaging
• Are pregnant with multiples (twins, triplets)
• Have a uterine fetal demise

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Conservative Management for Placenta Accreta Spectrum (PAS)	Conservative management for placenta accreta spectrum (PAS)	Subjects who are randomized to to conservative management will undergo a cesarean delivery followed by a period of close observation in the operating room for 30-45 minutes to be sure there is no excessive bleeding or risk to keep the placenta inside
Hysterectomy at time of delivery for Placenta Accreta Spectrum (PAS)	Cesarean hysterectomy for placenta accreta spectrum (PAS)	Subjects who are randomized to cesarean hysterectomy will undergo a cesarean delivery followed immediately by hysterectomy to remove the placenta and uterus together

Primary Outcome Measures

Name	Time	Method
Number of patients completing the surgical treatment to which they are allocated	Day of delivery	Number of patients completing the surgical treatment to which they are allocated (hysterectomy or conservative management) on the day of delivery.

Secondary Outcome Measures

Name	Time	Method
Number of enrolled who are lost to follow-up through study end (inverse of retention).	Up to 6 weeks postpartum	Number of enrolled who are lost to follow-up through study end (inverse of retention).
Number of enrolled completing full postpartum follow-up visit schedule.	Up to 6 weeks postpartum	Number of enrolled completing full postpartum follow-up visit schedule.
Number of eligible people approached for enrollment.	20 weeks gestation through day of delivery	Number of eligible people approached for enrollment.
Number of enrolled completing hysterectomy on day of delivery.	Day of delivery	Number of enrolled completing hysterectomy on day of delivery.
Number of enrolled completing conservative management on day of delivery.	Day of delivery	Number of enrolled completing conservative management on day of delivery.
Number of eligible people randomized.	From time of consent up to one week (1-7 days) before planned delivery	Number of eligible people randomized.
Number of enrolled who don't complete their allocated treatment (drop-out).	Up to 6 weeks postpartum	Number of enrolled who don't complete their allocated treatment (drop-out).

Trial Locations

Locations (1)

University of Utah; 🇺🇸 Salt Lake City, Utah, United States